Substituted thiazoles for the treatment of inflammation

A compound of Formula I ##STR69## wherein R.sup.1 is selected from hydrido, halo, amino, C.sub.1 -C.sub.10 alkoxy, cyano, nitro, hydroxyl, aminocarbonyl, acyl, C.sub.1 -C.sub.10 alkylaminocarbonyl, C.sub.6 -C.sub.12 arylaminocarbonyl, C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.2 -C.sub.10 alkynyl, C.sub.1 -C.sub.10 haloalkyl, C.sub.1 -C.sub.10 haloalkoxy, C.sub.1 -C.sub.10 alkylamino, C.sub.6 -C.sub.12 arylamino, C.sub.1 -C.sub.10 alkyl-C.sub.6 -C.sub.12 -arylamino, C.sub.6 -C.sub.12 aryl-C.sub.1 -C.sub.10 -alkylamino, carboxyl, C.sub.1 -C.sub.10 carboxyalkyl, C.sub.1 -C.sub.10 alkoxycarbonyl, C.sub.1 -C.sub.10 alkoxycarbonylalkyl, C.sub.1 -C.sub.10 alkylamino-C.sub.1 -C.sub.10 alkyl, 5-10 membered heterocyclic-C.sub.1 -C.sub.10 -alkyl, C.sub.6 -C.sub.12 aryl-C.sub.1 -C.sub.10 alkyl, C.sub.1 -C.sub.10 cyanoalkyl, N-C.sub.1 -C.sub.10 -alkylsulfonylamino, 5-10 membered heteroarylsulfonyl-C.sub.1 -C.sub.10 -alkyl, 5-10 membered heteroarylsulfonyl-C.sub.1 -C.sub.10 -haloalkyl, C.sub.6 -C.sub.12 aryloxy-C.sub.1 -C.sub.10 -alkyl, C.sub.6 -C.sub.12 aryl-C.sub.1 -C.sub.10 -alkyloxy-C.sub.1 -C.sub.10 -alkyl, C.sub.6 -C.sub.12 aryl optionally substituted at a substitutable position with one or more radicals selected from halo, C.sub.1 -C.sub.10 alkyl, C.sub.1 -C.sub.10 alkoxy, C.sub.1 -C.sub.10 alkylthio, C.sub.1 -C.sub.10 alkylsulfinyl, C.sub.1 -C.sub.10 haloalkyl, C.sub.1 -C.sub.10 haloalkoxy, C.sub.1 -C.sub.10 carboxyalkyl, C.sub.1 -C.sub.10 alkoxycarbonyl, aminocarbonyl, amino, acyl and C.sub.1 -C.sub.10 alkylamino, and 5-10 membered heterocyclic optionally substituted at a substitutable position with one or more radicals selected from halo, C.sub.1 -C.sub.10 alkyl, C.sub.1 -C.sub.10 alkoxy, C.sub.1 -C.sub.10 alkylthio, C.sub.1 -C.sub.10 alkylsulfinyl, C.sub.1 -C.sub.10 haloalkyl, C.sub.1 -C.sub.10 haloalkoxy, C.sub.1 -C.sub.10 carboxyalkyl, C.sub.1 -C.sub.10 alkoxycarbonyl, aminocarbonyl, amino, acyl and C.sub.1 -C.sub.10 alkylamino;

• wherein R.sup.2 is selected from C.sub.6 -C.sub.12 aryl, C.sub.3 -C.sub.10 cycloalkyl, C.sub.3 -C.sub.10 cycloalkenyl and 5-10 membered heterocyclic;
• wherein R.sup.2 is optionally substituted at a substitutable position with one or more radicals selected from halo, C.sub.1 -C.sub.10 alkylthio, C.sub.1 -C.sub.10 alkylsulfinyl, C.sub.1 -C.sub.10 alkylsulfonyl, C.sub.1 -C.sub.10 haloalkylsulfonyl, sulfamyl, C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.2 -C.sub.10 alkynyl, cyano, carboxyl, C.sub.1 -C.sub.10 carboxyalkyl, C.sub.1 -C.sub.10 alkoxycarbonyl, aminocarbonyl, acyl, N-mono-C.sub.1 -C.sub.10 -alkylaminocarbonyl, N-mono-C.sub.6 -C.sub.12 -arylaminocarbonyl, N,N-di-C.sub.1 -C.sub.10 -alkylaminocarbonyl, N-C.sub.1 -C.sub.10 -alkyl-N-C.sub.6 -C.sub.12 -arylaminocarbonyl, C.sub.1 -C.sub.10 haloalkyl, hydroxyl, C.sub.1 -C.sub.10 alkoxy, C.sub.1 -C.sub.10 hydroxyalkyl, C.sub.1 -C.sub.10 haloalkoxy, amino, N-C.sub.1 -C.sub.10 -alkylamino, N,N-di-C.sub.1 -C.sub.10 -alkylamino, 5-10 membered heterocyclic and nitro;
• and
• wherein R.sup.3 is selected from C.sub.6 -C.sub.12 aryl, C.sub.3 -C.sub.10 cycloalkyl, C.sub.3 -C.sub.10 cycloalkenyl and 5-10 membered heterocyclic;
• wherein R.sup.3 is optionally substituted at a substitutable position with one or more radicals selected from halo, C.sub.1 -C.sub.10 alkylthio, C.sub.1 -C.sub.10 alkylsulfinyl, C.sub.1 -C.sub.10 alkylsulfonyl, C.sub.1 -C.sub.10 haloalkylsulfonyl, sulfamyl, C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.2 -C.sub.10 alkynyl, cyano, carboxyl, C.sub.1 -C.sub.10 carboxyalkyl, C.sub.1 -C.sub.10 alkoxycarbonyl, aminocarbonyl, acyl, N-mono-C.sub.1 -C.sub.10 -alkylaminocarbonyl, N-mono-C.sub.6 -C.sub.12 -arylaminocarbonyl, N,N-di-C.sub.1 -C.sub.10 -alkylaminocarbonyl, N-C.sub.1 -C.sub.10 -alkyl-N-C.sub.6 -C.sub.12 -arylaminocarbonyl, C.sub.1 -C.sub.10 haloalkyl, C.sub.1 -C.sub.10 haloalkoxy, hydroxyl, C.sub.1 -C.sub.10 alkoxy, C.sub.1 -C.sub.10 hydroxyalkyl, amino, N-C.sub.1 -C.sub.10 -alkylamino, N,N-di-C.sub.1 -C.sub.10 -alkylamino, 5-10 membered heterocyclic and nitro;
• provided one of R.sup.2 and R.sup.3 is phenyl substituted with methylsulfonyl, C.sub.1 haloalkylsulfonyl or sulfamyl;
• or a pharmaceutically-acceptable salt thereof.